Publication number: 20250145635
Abstract: A compound containing a bis(azanylylidene) sulfonyl structure of formula (I) as a PKR agonist and/or USP9X inhibitor, which can be used for treating related diseases mediated and regulated by PKR and USP9X, wherein the related diseases comprise, but are not limited to: sickle-cell anemia, ?-thalassemia, hereditary non-spherocytic hemolytic anemia, hemolytic anemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, congenital anemia, anemia of chronic diseases, colorectal cancer, kidney cancer, pancreatic cancer, breast cancer, lung cancer, esophageal cancer, melanoma, lymphoma, glioblastoma, or multiple myeloma.
Type:
Application
Filed:
December 21, 2022
Publication date:
May 8, 2025
Inventors:
Jianzong LI, Zao WANG, Shunchun ZHAO, TAO SHAO, Ruijie ZHOU, Jing WANG, Xiao HU, Yeye WANG, Xiaodong ZHANG, Jun TANG, Yuanqing TANG
Patent number: 12288918
Abstract: There is provided a phase shifter having a phase shift region and a peripheral region, and including a first substrate, a second substrate and a dielectric layer between such two substrates; the first substrate includes a first dielectric substrate, a first electrode and a first auxiliary structure; the second substrate includes a second dielectric substrate, a second electrode and a second auxiliary structure; the phase shift region includes overlapping regions; the first electrode and the second electrode are located in the phase shift region, and have orthographic projections, on the first dielectric substrate, overlapped at least partially in the overlapping regions; the first auxiliary structure is in the peripheral region and on a side, close to the dielectric layer, of the first dielectric substrate; the second auxiliary structure is in the peripheral region and on a side, close to the dielectric layer, of the second dielectric substrate.
Type:
Grant
Filed:
January 27, 2022
Date of Patent:
April 29, 2025
Assignees:
Beijing BOE Sensor Technology Co., Ltd., BOE TECHNOLOGY GROUP CO., LTD.
Inventors:
Xiaobo Wang, Haocheng Jia, Chuncheng Che, Zhifeng Zhang, Cuiwei Tang, Yong Liu, Honggang Liang, Sheng Chen, Xueyan Su, Hailong Lian, Yi Ding, Jing Xie, Wei Zhang, Weisi Zhou, Meng Wei, Jing Wang, Zhenguo Zhang, Feng Qu
Publication number: 20250108106
Abstract: This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that can comprise STING polypeptide, a nucleic acid encoding said STING polypeptide, a STING inhibitor, a STING activator, a STING agonist, a STING antagonist, a STING modulating molecule, or a combination thereof. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine. This disclosure is also directed to a method for treating or preventing a disease using the pharmaceutical composition. The disease can include infectious diseases caused by viruses or other pathogens, for example, influenza, rabies, or respiratory illnesses such as severe acute respiratory syndrome (SARS) caused by coronaviruses, such as MERS-CoV, SARS-CoV, and Coronavirus Disease 2019 (COVID-19) caused by the virus SARS-CoV-2 and its variants.
Type:
Application
Filed:
September 10, 2024
Publication date:
April 3, 2025
Inventors:
Lu Lu, Ray Yin, Shibo Jiang, Zezhong Liu, Ming Hsieh, Jie Zhou, Xinling Wang, Qian Wang, Wei XU, Jing Pan, Yubei Zhang, Kai Qi, Qun Sun, Lin Wang, Zhiying Zou, Chunlin Tao